Tomohiko YAMAZAKI

Prof. Dr. Tomohiko YAMAZAKI

Res Center Macromolecules and Biomaterials, National Institute for Materials Science, Tsukuba, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
KOSUKE MINAMIKOSUKE MINAMI
KOSUKE MINAMI
YKYuki Kasuya
Yuki Kasuya
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
QJQingmin Ji
Qingmin Ji
WNWaka Nakanishi
Waka Nakanishi
Katsuhiko ArigaKatsuhiko Ariga
Katsuhiko Ariga

8 July 2015 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
Venkata  KrishnanVenkata Krishnan
Venkata Krishnan
YKYuki Kasuya
Yuki Kasuya
QJQingmin Ji
Qingmin Ji
MSMarappan Sathish
Marappan Sathish
Lok ShresthaLok Shrestha
Lok Shrestha
Katsuhiko ArigaKatsuhiko Ariga
Katsuhiko Ariga

1 April 2007 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
NKNoriko Kakehi
Noriko Kakehi
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
WTWakako Tsugawa
Wakako Tsugawa
Koji SodeKoji Sode
Koji Sode

1 February 2016 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
Koji SodeKoji Sode
Koji Sode
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
ILInyoung Lee
Inyoung Lee
THTakuya Hanashi
Takuya Hanashi
WTWakako Tsugawa
Wakako Tsugawa
Studies regarding biofuel cells utilizing biocatalysts such as enzymes and microorganisms as electrocatalysts have been vigorously conducted over the last two decades. Because of their environmental safety and sustainability, biofuel cells are expected to be used as clean power generators. Among several principles of biofuel cells, enzyme fuel cells have attracted significant attention for their use as alternative energy sources for future implantable devices, such as implantable insulin pumps and glucose sensors in artificial pancreas and pacemakers. However, the inherent issue of the biofuel cell principle is the low power of a single biofuel cell. The theoretical voltage of biofuel cells is limited by the redox potential of cofactors and/or mediators employed in the anode and cathode, which are inadequate for operating any devices used for biomedical application. These limitations inspired us to develop a novel biodevice based on an enzyme fuel cell that generates sufficient stable power to operate electric devices, designated "BioCapacitor." To increase voltage, the enzyme fuel cell is connected to a charge pump. To obtain a sufficient power and voltage to operate an electric device, a capacitor is used to store the potential generated by the charge pump. Using the combination of a charge pump and capacitor with an enzyme fuel cell, high voltages with sufficient temporary currents to operate an electric device were generated without changing the design and construction of the enzyme fuel cell. In this review, the BioCapacitor principle is described. The three different representative categories of biodevices employing the BioCapacitor principle are introduced. Further, the recent challenges in the developments of self-powered stand-alone biodevices employing enzyme fuel cells combined with charge pumps and capacitors are introduced. Finally, the future prospects of biodevices employing the BioCapacitor principle are addressed.

1 March 2009 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
THTakuya Hanashi
Takuya Hanashi
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
WTWakako Tsugawa
Wakako Tsugawa
SFStefano Ferri
Stefano Ferri
DNDaisuke Nakayama
Daisuke Nakayama
Koji SodeKoji Sode
Koji Sode

26 September 2011 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
WMWenjun Meng
Wenjun Meng
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
YNYuuki Nishida
Yuuki Nishida
AHand Nobutaka Hanagata
and Nobutaka Hanagata
Background: Unmethylated cytosine-guanine (CpG) motif-containing oligodeoxynucleotides (ODNs) have been well characterized as agonists of Toll-like receptor 9 (TLR9). ODNs with a phosphorothioate (PTO) backbone have been studied as TLR9 agonists since natural ODNs with a phosphodiester (PD) backbone are easily degraded by a serum nuclease, which makes them problematic for therapeutic applications. However, ODNs with a PTO backbone have been shown to have undesirable side effects. Thus, our goal was to develop nuclease-resistant, PD ODNs that are effective as human TLR9 (hTLR9) agonists.Results: The sequence of ODN2006, a CpG ODN that acts as an hTLR9 agonist, was used as the basic CpG ODN material. The 3'-end modification of ODN2006 with a PD backbone (PD-ODN2006) improved its potential as an hTLR9 agonist because of increased resistance to nucleolytic degradation. Moreover, 3'-end modification with oligonucleotides showed higher induction than modification with biotin, FITC, and amino groups. Further, enhancement of hTLR9 activity was found to be dependent on the number of CpG core motifs (GTCGTT) in the PD ODN containing the 3'-end oligonucleotides. In particular, ODN sequences consisting of two to three linked ODN2006 sequences with a PD backbone (e.g., PD-ODN2006-2006 and PD-ODN2006-2006-2006) acted as effective agonists of hTLR9 even at lower concentrations.Conclusions: This study showed that PD-ODN2006-2006 and PD-ODN-2006-2006-2006 can be used as potentially safe agonists for hTLR9 activation instead of CpG ODNs with a PTO backbone. We propose these CpG ODNs consisting of only a PD backbone as a novel class of CpG ODN.